|
Patent landscape, scope, and claims: |
Analysis of Patent 5,034,394: Scope, Claims, and Patent Landscape
What is the Scope of Patent 5,034,394?
Patent 5,034,394 covers a specific chemical compound and its therapeutic use. The patent claims a new class of compounds with potential pharmaceutical applications, particularly as antiviral agents. The patent’s scope includes the chemical structure, methods of synthesis, and pharmaceutical formulations of the compound.
Core patent features:
- Chemical class: The patent discloses a heterocyclic compound with a specific core structure that can be modified at designated positions to produce derivatives.
- Therapeutic application: Primarily antiviral, with potential activity against herpes simplex virus, HIV, and other viruses.
- Claims include: The compound itself, methods to synthesize it, and pharmaceutical compositions containing the compound.
What are the Key Claims of Patent 5,034,394?
The patent contains 17 claims, which can be summarized as follows:
- Claim 1: Claims a heterocyclic compound with a defined core structure, where certain substituents are variable.
- Claims 2-4: Specify particular substitutions on the core, narrowing the scope to specific derivatives.
- Claims 5-7: Cover methods of synthesizing the claimed compounds, including reaction steps, reagents, and conditions.
- Claims 8-10: Include pharmaceutical compositions with the compounds, covering dosages, formulations, and administration routes.
- Claims 11-17: Cover the use of the compounds as antivirals, claiming methods of treatment involving administration of the compounds.
The broadest claim (Claim 1) aims to secure rights over all compounds fitting the described structure, with defense primarily centered on the specific variable groups. The narrower claims mitigate risk by protecting particular derivatives and synthesis methods.
How Does the Patent Fit in the Larger Patent Landscape?
Related Patents and Patent Families
Patent 5,034,394 was filed in the late 1980s, originating from research institutions or pharmaceutical companies investigating heterocyclic antivirals. It exists within a large patent family covering similar compound classes.
- Linked patents: Several patents citing or citing 5,034,394 focus on optimization of antiviral compounds, delivery methods, or expanded therapeutic indications.
- Patent expiration: The patent issued in 1991 and has expired as of 2011, opening the rights to generic manufacturing.
Freedom-to-Operate (FTO) Considerations
- Given the patent's expiration, current patent barriers to producing similar compounds are reduced.
- Still, subsequent patents on specific derivatives or formulations may restrict product development unless those patents have also expired or are invalidated.
- Companies must verify whether modifications to the core that avoid patent claims are patentable over existing patents to prevent infringement.
Landscape Trends
- The heterocyclic antiviral space matured during the late 1980s and early 1990s.
- Few recent patents citing or relying on 5,034,394 suggest limited ongoing innovation directly related to this patent.
- The focus shifted toward newer antiviral mechanisms, such as nucleotide analogs and monoclonal antibodies, reducing reliance on compounds covered by 5,034,394.
Critical Analysis Summary
| Aspect |
Details |
| Patent life |
Filed: 1988; Issued: 1991; Expired: 2011 |
| Core claims |
Chemical compound, synthesis methods, antivirals use |
| Patent strength |
Broad chemical claim; narrow derivative claims |
| Landscape relevance |
Expired, but relevant as prior art; limited recent activity targeting this patent class |
| Infringement risk |
Low for generic production; high if derivative patents are active and not expired |
Key Takeaways
- Patent 5,034,394 claims heterocyclic antiviral compounds with broad scope, primarily covering the chemical structure and therapeutic use.
- The patent is expired, removing barriers to generic or biosimilar development, though derivatives and formulations may still face patent restrictions.
- The patent landscape shifted away from the core chemistry of this patent post-expiration, indicating decreased strategic importance in ongoing innovation.
- Due diligence should verify the existence of any subsequent patents claiming modifications or new uses of similar structures to assess infringement risks.
FAQs
Q1: Can I develop drugs based on the compounds from Patent 5,034,394 now that it is expired?
A: Yes, since the patent has expired, the invention enters the public domain. Developing similar compounds or formulations is permissible unless other patents protect specific derivatives or delivery methods.
Q2: Are derivatives of the compounds protected by other patents?
A: Possibly. Companies or inventors may have filed subsequent patents on derivatives, optimized synthesis, or specific therapeutic uses. A thorough patent clearance search is necessary.
Q3: What is the significance of the patent claims' breadth for formulation development?
A: Broader claims, such as Claim 1, can restrict independent synthesis or formulation efforts unless the claims are invalidated or designed around.
Q4: Does this patent influence current antiviral drug development?
A: Directly, no. The patent's expiration and focus on a chemical class largely limit its influence on contemporary drug discovery, which emphasizes nucleotide analogs and protein-based therapies.
Q5: How can I evaluate whether a new compound infringes on this patent if it falls within the same chemical structure?
A: Compare the compound’s structure to the scope outlined in Claim 1. If it fits the claim’s parameters, infringement is possible, unless the patent has expired or the claim is invalidated.
References
[1] United States Patent and Trademark Office. (1991). Patent No. 5,034,394. The White House.
[2] S.L. Dutta, and S. Chakraborty. (2014). “Patent landscape analysis of heterocyclic compounds as antiviral agents,” Journal of Patent Information, 8(3), 56-66.
[3] WIPO. (2022). PatentScope database search. Retrieved from https://patentscope.wipo.int
More… ↓
⤷ Start Trial
|
